| Perhexilene: effects on hepatic lysosomal function in rats. | |
| | |
MedLine Citation:
|
PMID: 2706806 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
1. Perhexilene, a long-acting anti-anginal drug, can induce adverse effects on the liver which may be dose-dependent. At high concentrations, perhexilene causes marked morphological changes in hepatocyte lysosomes. The current study examined the effect of 'therapeutic' doses of perhexilene on hepatic lysosomal function, particularly the biliary release of lysosomal enzymes, using an isolated perfused rat liver (IPRL) model. 2. Pharmacokinetic studies demonstrated that clearance of single doses of perhexilene by the perfused rat liver was dose-dependent and established a 'therapeutic' dose of 0.6 mg using the IPRL. A 5 day pretreatment regimen of 20 mg/kg per day was shown to produce 'therapeutic' perhexilene concentrations of 150-210 ng/ml. 3. At perhexilene concentrations equating the 'therapeutic' range in man, the major effect of perhexilene was at the biliary pole of the hepatocyte. In 5 day pretreatment dose studies, lysosomal enzyme excretion into bile was markedly increased. In single dose studies, the increase in biliary lysosomal enzyme output partially reflected an increase in bile water production which was not seen with the 5 day pretreatment regimen. Hepatic and perfusate lysosomal enzyme activities were not affected. 4. This selective effect of perhexilene on hepatocyte-to-bile lysosomal excretion may reflect intracellular lysosomal drug localization. |
| | |
Authors:
|
R B Sewell; J D Horowitz; S A Grinpukel; G Martin |
Related Documents
:
|
22320786 - A novel technique to enable experimental validation of deformable dose accumulation. 17854266 - Effect of safranal, a constituent of crocus sativus (saffron), on methyl methanesulfona... 19173766 - The distribution and accumulation of fucoxanthin and its metabolites after oral adminis... 2061426 - The activities of drug-metabolizing enzymes in goats treated orally with the latex of c... 23613806 - Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrop... 21464466 - Auditory effects of developmental exposure to purity-controlled polychlorinated bipheny... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental pharmacology & physiology Volume: 16 ISSN: 0305-1870 ISO Abbreviation: Clin. Exp. Pharmacol. Physiol. Publication Date: 1989 Jan |
Date Detail:
|
Created Date: 1989-06-07 Completed Date: 1989-06-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0425076 Medline TA: Clin Exp Pharmacol Physiol Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 25-32 Citation Subset: IM |
Affiliation:
|
Gastroenterology Unit, Austin Hospital, Heidelberg, Victoria, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylglucosaminidase
/
metabolism Animals Bile / drug effects, enzymology Dose-Response Relationship, Drug Female Glucuronidase / metabolism Liver / drug effects*, enzymology Lysosomes / drug effects*, enzymology, pathology Metabolic Clearance Rate Models, Biological Perhexiline / pharmacokinetics, pharmacology* Rats Rats, Inbred Strains |
| Chemical | |
Reg. No./Substance:
|
6621-47-2/Perhexiline; EC 3.2.1.31/Glucuronidase; EC 3.2.1.52/Acetylglucosaminidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blood pressure, plasma and pituitary prolactin responses to bromocriptine in New Zealand genetically...
Next Document: Effect of magnesium depletion and potassium depletion and chlorothiazide on intracellular pH in the ...